JWS
HZNP

Juncture Wealth Strategies’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Juncture Wealth Strategies’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-15,513
Closed -$562K – 105
2019
Q4 		$562K Buy
15,513
+148
+1% +$4.54K 0.44% 56
2019
Q3 		$418K Buy
+15,365
New +$397K 0.37% 73

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Juncture Wealth Strategies's HZNP Position: Q1 2020 in Review

Juncture Wealth Strategies sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2020, closing a stake of 15,513 shares — an estimated $562K sold.

Juncture Wealth Strategies first reported a position in HZNP in Q3 2019 and held it in 2 quarters. The position peaked at $562K in Q4 2019. 295 funds tracked by Wall St. Rank hold HZNP as of Q1 2020.

  • Juncture Wealth Strategies reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2020 after selling out during the quarter.
  • Juncture Wealth Strategies sold 15,513 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2020, an estimated $562K.
  • Juncture Wealth Strategies first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2019 and held it in 2 quarters.
  • Juncture Wealth Strategies's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $562K in Q4 2019.
  • 295 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2020.

Based on Juncture Wealth Strategies's 13F filing for Q1 2020, filed 21 Apr 2020.